title: [Not Available].
abstract: Oxcarbazepine is an analogue of carbamazepine, used for the treatment of partial seizure with or without secondary generalization. The two forms R and S of the mono-hydroxylated derivatives (MHD) are responsible for most of the anti-convulsant activity and it is the concentrations of MHD that are relevant in therapeutic drug monitoring (TDM). Analysis of currently literature provides no well-established relationship between plasma concentration of MHD and efficiency or toxicity. Although there is not a validated therapeutic range, the residual concentrations of usually observed therapeutic MHD are situated between 12 and 30 mg/L. In certain pathological or physiological circumstances, the pharmacokinetic variability of the oxcarbazepine can be considerable, but this strong unpredictability does not nevertheless justify the TDM of the MHD. Based on the available evidence, TDM of MHD is not routinely warranted but may be possibly useful in specific situations such as pregnancy or renal insufficiency.
authors.affiliation: Service de Pharmacologie Clinique, CHU de Nantes, Nantes, France; EA 4275 Biostatistique, Recherche Clinique et Mesures Subjectives en Santé, Faculté de Médecine-Pharmacie, Université de Nantes, France. Electronic address: regis.bouquie@chu-nantes.fr.
authors.forename: Régis
authors.initials: R
authors.lastname: Bouquié
authors.affiliation: Service de Pharmacologie Clinique, CHU de Nantes, Nantes, France; EA 4275 Biostatistique, Recherche Clinique et Mesures Subjectives en Santé, Faculté de Médecine-Pharmacie, Université de Nantes, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Dailly
authors.affiliation: Laboratoire de Pharmacologie Biologique, CHU Pontchaillou, Rennes, France.
authors.forename: Danièle
authors.initials: D
authors.lastname: Bentué-Ferrer
keywords: MHD; Trileptal®; oxcarbazepine; oxcarbazépine; suivi thérapeutique pharmacologique; therapeutic drug monitoring